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http://dx.doi.org/10.1016/j.jacl.2015.05Abstract: Homozygous familial hypercholesterolaemia (HoFH) is a rare genetic disease characterised
by markedly elevated plasma levels of low-density lipoprotein-cholesterol (LDL-C). Lomitapide is a
microsomal triglyceride transfer protein (MTP) inhibitor approved as an adjunct to other lipid-lowering
therapies (LLTs), with or without lipoprotein apheresis (LA), for the treatment of adult HoFH. Diet
with ,20% calories from fat is required. Due to a varying genetic and phenotypic profile of patients
with HoFH, individual patients may respond to therapy differently; therefore examining individual
cases in a ‘real-world’ setting provides valuable information on the effective day-to-day management
of HoFH cases. Four HoFH cases were selected for analysis and discussion: a 20-year-old female com-
pound heterozygote; a 62-year old female homozygote; a 42-year-old female compound heterozygote;
and a 36-year-old male homozygote. Each patient was commenced on lomitapide according to the pre-
scribed protocol and subjected to routine follow-up. All four patients experienced clinically meaningful
reductions in LDL-C levels of 35–73%. Three of the patients had evidence of steatosis or mildly
elevated liver function tests) before lomitapide was started, but effects of lomitapide on hepatic func-
tion were not universal. Three of the patients experienced gastrointestinal adverse events, but were
managed with appropriate dietary control. Lomitapide is an effective adjunct LLT in the management
of patients with HoFH, with or without LA. Real-world use of lomitapide has a side-effect profile
consistent with clinical trials and one that can be managed by adherence to recommendations on
dose escalation, dietary modification and dietary supplements.
 2015 National Lipid Association. All rights reserved.Introduction
Homozygous familial hypercholesterolemia (HoFH) is a
rare genetic disease caused most frequently by loss-of-
function mutations in the low-density lipoprotein receptort of Internal Medicine, Erasmus
lands.
erasmusmc.nl
for publication May 7, 2015.
ociation. All rights reserved.
.001(LDL-R) gene1,2 or less frequently in other genes that result
in similar phenotypes (such as loss-of-function mutations in
APOB and/or gain of function in the PCSK9 gene, or homo-
zygosity for mutations in LDRAP1).1,2 HoFH is character-
ized by markedly and varying elevated plasma levels of
low-density lipoprotein cholesterol (LDL-C).3 Common
(but not universal) signs of HoFH include cutaneous xan-
thoma and early-onset atherosclerosis.3–5 In untreated
patients, premature atherosclerosis develops, and patients
may die prematurely.1,2
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Society has defined treatment targets in HoFH in adults
as,2.5 mmol/L (w100 mg/dL)6 and in adults with clinical
cardiovascular disease (CVD) as ,1.8 mmol/L (w70 mg/
dL).6 Conventional treatments for HoFH have included
optimizing lifestyle, such as adopting a low-cholesterol
diet, and lipid-lowering therapies (LLTs), such as statins.7
However, because of the lack of or deficiency in LDL-R
function that characterize most HoFH patients, conven-
tional lipid-lowering drugs that rely on upregulation of
expression of intact LDL-R pathways (such as statins) do
not result in adequate responses in many patients.4,7–9
Therefore, HoFH treatment often includes lipoprotein
apheresis (LA).8,10,11
LA can acutely reduce LDL-C levels in the blood
by #50% and delay the onset of atherosclerosis.8,10,11
However, the kinetics of LDL-C is such that levels rebound
to baseline within 2 weeks.12 Even with LA, patients can
endure persistently high levels of LDL-C and remain at
risk of developing premature CVD.13 Given the limitations
of therapies for HoFH, recent research has focussed on the
development of agents that circumvent the LDL-R or
disrupt the synthesis of apolipoprotein B or of the LDL pre-
cursor very low–density-lipoprotein.14,15
Lomitapide is a microsomal triglyceride transfer protein
(MTP) inhibitor. It is approved in the United States,
European Union, Canada, and Mexico as an adjunct to
other LLTs (including LA) for the treatment of adult
patients with HoFH.16,17 MTP is a key protein in the assem-
bly and secretion of apolipoprotein B–containing lipopro-
teins in the liver and intestine, and lomitapide, therefore,
acts to lower LDL-C in a manner independent of LDL-R
expression.18
In a pivotal phase 3 study of 29 patients with HoFH
(AEGR733-005; NCT00730236), individualized dosing
with lomitapide resulted in a mean 40% to 50% (depending
on type of analysis used) reduction in LDL-C levels
(P , .001) at the end of the efficacy phase (week 26) and
a mean z 40% reduction at the conclusion of the
78-week study.19 Adverse events (AEs) were primarily
gastrointestinal (GI) disturbances (mild to moderate) and
elevations in hepatic transaminase levels. Six patients dis-
continued the study: 5 due to AEs (4 GI and 1 headache),
and 1 patient withdrew consent. No patient discontinued
the trial due to liver toxicity.19 Patients on lomitapide are
required to adhere to a low-fat eating plan to minimize
GI issues and set forth strict parameters for managing and
monitoring hepatic transaminase levels.
In the clinical trial setting, significant efficacy was
demonstrated, along with an understanding of the risk
profile of lomitapide. However, little information has been
presented on the benefit and/or risk profile of lomitapide
and patient management in real-world clinical use. The aim
of the present case series was to review four individual real-
world patients with HoFH who received lomitapide to
illustrate how these patients responded to therapy and todemonstrate how side effects were managed in the clinical
practice setting.Case reports
Patient 1
Patient 1 is from the Netherlands and is treated at the
Cardiovascular Genetics Outpatient Clinic of the Erasmus
Medical Center, Rotterdam. She is a 20-year-old female
with loss-of-function compound heterozygous FH caused
by 2 different severe mutations in the LDLR gene: a
2.5-kbase deletion from exon 7 and 8 of LDLR (Cape
Town: 2 mutations) and a 4.4-kbase duplication in exon
12 (Leiden-3 mutation; Table 1). As a result, this patient
is LDL-R negative.
The patient was initially diagnosed with HoFH at age
3 years and had received treatment with conventional LLT
because the age of 4. Despite maintenance therapy with
oral atorvastatin (80 mg, daily) and colesevelam (1250 mg,
twice daily) for 13 years, total cholesterol levels ranged
from 9.9 mmol/L to peak at 18.9 mmol/L, and LDL-C
levels ranged from 7.5 to 17.8 mmol/L (290–688 mg/dL).
In January 2014 (at the age of 20 years), the patient was
started on lomitapide (5 mg, daily). The dose was escalated
stepwise to 30 mg, daily. After initiation of lomitapide
(5 mg), LDL-C levels decreased from 14.11 mmol/L (566
mg/dL) to 13.8 mmol/L (534 mmol/L) in 2 months. Over
the course of 5 months as lomitapide dose escalated up to
20 mg, levels of LDL-C, total cholesterol, and high-density
lipoprotein-cholesterol (HDL-C) all declined. With
increasing dose (30 mg), LDL-C levels were suppressed
to their lowest level of 2.4 mmol/L (93 mg/dL), thereby
representing an 83% reduction over 8 months (Fig. 1;
Table 2).
Levels of total cholesterol were reduced from
17.3 mmol/L (669 mg/dL) before therapy to 6.1 mmol/L
(236 mg/dL) over the same period (Fig. 1; Table 2).
Overall, side effects with lomitapide therapy were
tolerable and primarily consisted of GI disturbances.
Specifically, at the 5 mg lomitapide dose level, the patient
complained of nausea and diarrhea during the initial 2 days
of treatment, but not beyond that point, and intervention for
GI AEs was not required. With escalation to 10 mg, side
effects remained tolerable if dietary advice was adhered
(diet with ,20% energy from fat) to, and the patient ate
regularly. Further escalation to 20 mg saw the return of
diarrhoea, some abdominal pain and stomach ‘‘rumblings.’’
However, the patient noted that these GI symptoms were
lessened if she ate every 2 hours. Initially, she did not have
additional side effects after dose escalation to 30 mg.
However, after 3 weeks, dose was reduced back to 20 mg
because of stomach discomfort, diarrhoea, and fatigue.
After returning to the 20 mg dose, the patient felt better and
did not have any further problems with side effects as long
Table 1 Baseline characteristics of the 4 cases
Patient
Age,
y/sex
BMI,
kg/m2
Prelomitapide
LDL-C level,
mmol/L (mg/dL)*
Mutation in LDLR gene
Allele 1 Allele 2
1 20/F 24.9 14.11 (546) 2.5-kb deletion in exons 7 and 8 4.4-kb duplication in exon 12
2 62/F 26.8 10.35 (400) 16-kb deletion in exons 7 to 15 16-kb deletion in exons 7 to 15
3 42/F 35.0 7.16 (277) 5-kb deletion in exons 13 to 15 2390-?_25831?del
4 36/M 22.4 7.3 (282) G-A substitution at base 1646 G-A substitution at base 1646
BMI, body mass index; F, female; LDL-C, low-density lipoprotein cholesterol; M, male.
*Not an untreated value due to background therapy.
Roeters van Lennep et al Clinical use of lomitapide in HoFH 609as she adhered to the prescribed diet (,20% calories from
fat). The patient did not experience any instances of
elevated transaminases at any dose of the drug.
This patient continues to be monitored every 3 months
for LDL-C and LFTs.
Patient 2
Patient 2 is also from the Netherlands and treated at the
Cardiovascular Genetics Outpatient Clinic of the Erasmus
Medical Center, Rotterdam. She is a 62-year-old woman
with a homozygous phenotype resulting from a loss-of-
function mutation in the LDLR (HAARLEM-1). The pa-
tient was initially diagnosed in 2014 after presentation
with peak LDL-C levels of 12.9 mmol/L (499 mg/dL)
and total cholesterol of 15.0 mmol/L (580 mg/dL;
Table 1). She had undergone percutaneous coronary inter-
vention and had 4 stents implanted in 2008. In 2010, she
was diagnosed with type-2 diabetes mellitus. In the
following 3 years, she experienced 2 episodes of statin-
induced rhabdomyolysis.
In February 2014, the patient was determined to be a
candidate for lomitapide therapy with the diagnosis of
HoFH on clinical grounds only as genetic testing was notFigure 1 Patient 1: lipid profiles with escalating doses of lomitapide. A
lation protocol in the approved prescribing information.17 HDL-C, hig
cholesterol.performed. Ultrasound and FibroScan procedures before
lomitapide initiation revealed moderate hepatic steatosis. A
hepatologist was consulted to determine if a liver biopsy
was warranted and whether these findings revealed a
contraindication for starting lomitapide treatment. The
hepatologist advised that with the established high sensi-
tivity of ultrasound, there would be no point in conducting a
liver biopsy, especially as biopsies are prone to sample
error. The combination of normal levels of aspartate
transaminase (AST) and alanine transaminase (ALT) and
normal Fibroscan on the one side and, the elevated risk of
CVD in this patient (evidenced by established CVD,
diabetes, and extremely high LDL-C levels) on the other,
tipped the risk–benefit balance in favor of commencing
lomitapide.
Lomitapide (5 mg, p.o.) was commenced in April 2014.
Levels of LDL-C, HDL-C, and total cholesterol declined
within 1 month of starting treatment. LDL-C levels reached
6.7 mmol/L (259 mg/dL) by May 2014 (46% reduction;
Fig. 2; Table 3).
AEs on the 5-mg dose included some loss of appetite
and some stomach discomfort, but no diarrhoea and no
evidence of elevated transaminase levels, and treatment did
not require modification. After 2-month treatment withrrows represent changes in lomitapide dose according to the esca-
h-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
Table 2 Patient 1: lomitapide treatment details and key lipid parameters
Week
TC, mmol/L
(mg/dL)
TG, mmol/L
(mg/dL)
HDL, mmol/L
(mg/dL)
LDL, mmol/L
(mg/dL)
ALT,
U/L
Lomitapide,
mg
Other
LLTs Intervention
0 17.30 (669) 1.84 (163) 1.35 (52) 14.11 (546) 17 — Ator80
10 16.30 (630) 0.95 (84) 0.95 (37) 13.75 (532) 22 5 Ator80
13 13.80 (534) 0.91 (81) 1.05 (41) 11.03 (427) 20 10 Ator80 Escalate lomitapide
18 8.10 (313) 0.57 (50) 1.02 (39) 6.63 (256) 27 20 Ator80 Escalate lomitapide
23 6.70 (259) 0.46 (41) 1.10 (43) 5.42 (210) 24 20 Ator80
27 6.10 (236) 0.41 (36) 1.13 (44) 4.64 (179) 26 20 Ator80
33 7.00 (271) 0.987 (77) 1.20 (46) 5.34 (206) 18 20 Ator80
38 7.80 (302) 0.63 (56) 1.18 (46) 5.98 (231) 15 20 Ator80 Escalate lomitapide
47 2.40 (93) 0.29 (26) 0.90 (35) 1.29 (50) 31 30 Ator80
50 4.00 (155) 0.28 (25) 1.00 (39) 2.86 (111) — 20 Ator80 Reduce lomitapide dose
ALT, alanine aminotransferase; Ator, atorvastatin (number denotes dose in mg); HDL, high-density lipoprotein; LDL, low-density lipoprotein; LLT,
lipid-lowering therapy; TC, total cholesterol; TG, triglycerides.
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lomitapide dose was escalated to 10 mg daily. Subse-
quently, levels of AST and ALT increased to more than
5-times the upper limit of normal (.5! ULN). Therefore,
according to the guidance from the lomitapide summary of
product characteristics, lomitapide was temporarily with-
held until the patient’s liver tests normalized, which was
achieved quickly. Lomitapide was restarted after 4 weeks,
and the patient was monitored regularly by liver function
tests (LFTs). However, after rechallenge with lomitapide
5 mg, her LDL-C decreased, but her ALT levels increased
again to .3! ULN. Therefore, treatment with lomitapide
was stopped permanently on 30 September, 2014. After
discontinuation of lomitapide treatment, LFTs decreased
again to normal levels.
Patient 3
Patient 3 is a 42-year-old female from Spain. She is a
compound heterozygote with a change of amino acid atFigure 2 Patient 2: lipid profiles with escalating doses of lomitapide. A
lation protocol in the approved prescribing information.17 HDL-C, hig
cholesterol.position 633 (R612H) in the LDLR (LDL-R defective) and
another copy number variation mutation 2390-?_25831?
del (LDL-R negative).
This patient was first seen in 1979 with a total
cholesterol level of 21.3 mmol/L at age 7 years. Initially,
she had been treated with Plasmaclear and the bile acid
sequestrant cholestyramine, and these had been moderately
successful in stabilizing total cholesterol at z13 mmol/L
and resulting in an LDL-C value of 11.4 mmol/L (previ-
ously, only total cholesterol had been monitored). With the
advent of lovastatin, and then with subsequent statins, the
patient was switched to a series of alternative LLTs
between 1991 and 2010: lovastatin 20 to 40 mg, simvastatin
20 mg, pravastatin 20 mg, fenofibrate 250 mg, and
bezafibrate 400 mg among others. Despite application of
these then novel therapies, LDL-C levels continued to
climb, eventually reaching 17.9 mmol/L.
During this period, the patient underwent a coronary
bypass and aortic valve replacement (in 2001, aged
29 years). Between 2010 and 2013, rosuvastatin 40 mg,rrows represent changes in lomitapide dose according to the esca-
h-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
Table 3 Patient 2: lomitapide treatment details and key lipid parameters
Week
TC, mmol/L
(mg/dL)
TG, mmol/L
(mg/dL)
HDL, mmol/L
(mg/dL)
LDL, mmol/L
(mg/dL)
ALT,
U/L
Lomitapide,
mg
Other
LLTs Intervention
0 12.60 (487) 3.08 (273) 1.10 (43) 10.35 (400) 16 — None
17 8.40 (325) 1.29 (114) 1.22 (47) 6.74 (261) 5 None
20 5.70 (220) 0.83 (74) 0.84 (32) 4.34 (168) 143 10 None Escalate lomitapide
21 5.30 (205) 0.94 (83) 0.90 (35) 3.94 (152) 230 — None Stop lomitapide
22 8.00 (309) 1.82 (161) 0.97 (38) 5.97 (231) 165 — None
22 9.70 (375) 2.00 (177) 1.10 (43) 7.63 (295) 138 — None
24 12.9 (499) 2.60 (230) 0.88 (34) 10.63 (411) 48 5 None Restart lomitapide 5 mg
25 10.60 (410) 1.45 (128) 0.77 (30) 8.83 (341) 27 5 None
27 7.60 (294) 0.93 (82) 1.62 (63) 6.14 (237) 56 5 None
29 7.40 (286) 0.96 (85) 0.85 (33) 5.98 (231) 86 5 None
30 7.80 (302) 1.13 (100) 0.92 (36) 6.23 (241) 67 5 None
31 8.20 (317) 1.00 (89) 0.96 (37) 6.58 (254) 81 5 None
38 7.20 (278) 1.08 (96) 0.91 (35) — 132 5 None Stop lomitapide
44 15.00 (580) 2.04 (181) 1.10 (43) 12.90 (500) 64 0 None
ALT, alanine aminotransferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LLT, lipid-lowering therapy; TC, total cholesterol; TG,
triglycerides.
Roeters van Lennep et al Clinical use of lomitapide in HoFH 611and atorvastatin 80 mg plus ezetimibe 10 mg were given. In
2014, this regimen was changed to rosuvastatin 40 mg,
ezetimibe 10 mg, and colesevelam 4! 625 mg (2.5 g/day;
maximal LLT). The patient’s LDL-C levels declined, but
then plateaued at w6.7 mmol/L (Fig. 3).
Beginning February 2014, the patient was started on
lomitapide with maintenance of maximal background LLT
(rosuvastatin 40 mg, ezetimibe 10 mg, and colesevelam
2.5 g/day). Baseline LDL-C was 7.1 mmol/L on initiation of
lomitapide (5 mg, daily). Doses of lomitapide were up-
titrated to 10 mg after 8 weeks on the 5-mg dose. LDL-C
levels fell to 5.0mmol/L for the 5-mg dose and to 4.7mmol/L
for the 10-mg dose (35% reduction; Fig 4; Table 4).
Levels of total cholesterol and triglyceride underwent
similar reductions (32% and 40%, respectively). Lipo-
protein (a) underwent a relatively modest reduction of
19%, and HDL-C levels remained essentially unchanged
(0.8–1.0 mmol/L; Fig. 4; Table 3).Figure 3 Patient 3: lipid profiles before lomitapide thThis patient had evidence of hepatic steatosis at baseline
according to qualitative ultrasound. In accordance with
advice for all patients receiving lomitapide, she was
advised to reduce dietary intake of fat to ,20%, as this
regimen has been shown to minimize potential GI AEs of
lomitapide. Also in accordance with the product label, the
patient was advised to take supplements of vitamin E and
essential fatty acids. Her weight reduced by 8.6%, and body
mass index fell from 35.5 kg/m2 to 32.5 kg/m2. Weight de-
creases are common in HoFH patients receiving lomitapide
and following label-mandated dietary advice.17
ALT levels were elevated from 23 IU/L (0.7! ULN) to
44 IU/L (1.3! ULN) with 5-mg lomitapide, but escalation
to 10 mg had no further effect. AST levels were elevated
slightly from 21 IU/L (0.6! ULN) at baseline to 36 IU/L
(1! ULN) with lomitapide 5 mg, but these resolved
slightly to 31 IU/L (0.9! ULN) on dose escalation. Levels
of gamma-glutamyltransferase increased very slightly in aerapy. LDL-C, low-density lipoprotein cholesterol.
Figure 4 Patient 3: lipid profiles with escalating doses of lomitapide. Arrows represent changes in lomitapide dose according to the esca-
lation protocol in the approved prescribing information.17 HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol.
612 Journal of Clinical Lipidology, Vol 9, No 4, August 2015dose-dependent manner, and vitamin-E levels were
increased slightly from 28.5 mg/mL between baseline and
lomitapide 10 mg.
Long-term monitoring of this patient will be conducted
using liver ultrasound every 6 months. LFT and lipid profile
will be determined every month until lomitapide dose is
stable. Then, analysis will be performed every 3 months. In
case an increase in transaminases is observed, an evaluation
by hepatologist will be considered.
The modest increase in transaminase levels were not
considered a cause of concern, and the patient remains on
therapy with lomitapide (7 months at the time of writing).
Patient 4
Patient 4 is a 36-year-old man from Italy with a
homozygous c.1646G.A substitution in exon 11 of the
LDLR (with no residual LDL-R functionality [LDL-R nega-
tive]). The patient had been treated with LA plus LLT (sim-
vastatin 60 mg) since the age of 9 years. Ezetimibe was
added when it became available in Italy (2004–2005). He
was also receiving metoprolol 50 mg, twice daily and
acenocumarole and lanzoprazole (both 15 mg/day). TheTable 4 Patient 3: lomitapide treatment details and key lipid param
Week
TC, mmol/L
(mg/dL)
TG, mmol/L
(mg/dL)
HDL, mmol/L
(mg/dL)
LDL, mmol/L
(mg/dL)
0 9.41 (364) 2.90 (257) 0.96 (37) 7.16 (277)
4 6.10 (236) 1.93 (171) 0.72 (28) 4.50 (174)
8 7.21 (279) 2.00 (177) 0.83 (32) 5.46 (211)
16 6.52 (252) 1.47 (130) 0.80 (31) 5.04 (195)
20 6.34 (245) 2.00 (177) 0.93 (36) 4.50 (174)
ALT, alanine aminotransferase; Ch, colesevelam (number denotes dose in
lipoprotein; LDL, low-density lipoprotein; LLT, lipid-lowering therapy; Ros,
triglycerides.patient abstained from alcohol and smoking, and had a
body mass index of 22.4 kg/m2.
Between December 2004 and January 2005 (age,
26 years), the patient underwent coronary angiography
followed by 2 coronary artery bypass grafts and mechanical
aortic valve replacement. The liver showed some signs of
loss of elasticity (7.5 kPa on FibroScan), but magnetic
resonance imaging ruled out the excess hepatic fat. Over a
10-year period, the LA regimen plus simvastatin and
ezetimibe lowered LDL-C to 2.5 to 4.0 mmol/L (immediate
post-LA readings), but LDL rebound kinetics meant that
LDL-C exposure remained high (Fig. 5).
Although this patient was satisfied with his LA plus LLT
treatment regimen, in March 2014, lomitapide became
available in his home region. Encouraged by the outcomes
observed in 2 local HoFH patients receiving lomitapide
who were able to stop LA (because of attainment of LDL-C
levels ,2.5 mmol/L), patient 4 requested the drug.
Lomitapide was administered according to the approved
regimen, commencing at a dose of 5 mg daily. LA was
unchanged, and simvastatin was maintained at 60 mg, and
ezetimibe at 10 mg. Lomitapide was up-titrated to 10 mg
2 weeks later. The authors note that in the lomitapideeters
ALT,
U/L
Lomitapide,
mg Other LLTs Intervention
20 0 Ros40/Eze10/Ch2.5
41 5 Ros40/Eze10/Ch2.5 Escalate lomitapide
46 5 Ros40/Eze10/Ch2.5
46 10 Ros40/Eze10/Ch2.5 Escalate lomitapide
43 10 Ros40/Eze10/Ch2.5
g/d); Eze, ezetimibe (number denotes dose in mg); HDL, high-density
rosuvastatin (number denotes dose in mg); TC, total cholesterol; TG,
Figure 5 Patient 4: pre and postapheresis LDL-C levels over 10 years. LDL-C, low-density lipoprotein cholesterol.
Roeters van Lennep et al Clinical use of lomitapide in HoFH 613clinical trial, 6 patients (of 23) had permanent changes to
their apheresis regimen from weeks 26 to 78 and that the
clinical benefit of reductions in background LLT, including
apheresis, is not certain.
In accordance with the prescribing information for
lomitapide, the patient was advised to adopt a low-fat
diet and to take the required supplements.
In May, 6 weeks after commencing lomitapide with no
effect on LDL-C, the lomitapide dose was further escalated
to 20 mg, daily. Simvastatin was reduced to 40 mg
according to the dosing recommendation in the lomitapide
prescribing information. With this regimen, LDL-C levels
were reduced by 73%, and total cholesterol by 62% (Fig. 6;
Table 5).
The patient experienced no GI disturbances with lomi-
tapide dose of ,10 mg; at 20 mg, he reported one episode
of diarrhoea (which he attributed to over-indulgence of
cake at a celebration party). The patient reported no GIFigure 6 Patient 4: change in lipid parameters according to lomitapid
the escalation protocol in the approved prescribing information.17 HDL
protein cholesterol.events when he adhered to the prescribed low-fat diet.
Levels of AST and ALT remained stable (43–44/42–44
IU/L, with a drop to 28/19 IU/L for the 10-mg dose of
lomitapide, respectively).
Patient 4 will undergo a regular monitoring schedule
with particular interest in clotting parameters, liver
enzymes, and bilirubin to detect signs of hepatotoxicity.
Liver elastometry was revaluated by FibroScan before
escalation to lomitapide 40 mg after 6 months of treatment.
Elasticity was improved (5.8 Kpa). Elastometry and mag-
netic resonance imaging will be conducted annually. Patient
4 remains on apheresis.
Discussion
The present study describes the real-world use of
lomitapide in 4 patients with HoFH. Before the initiation
of lomitapide, limited efficacy in reducing LDL-C wase dose. Arrows represent changes in lomitapide dose according to
-C, high-density lipoprotein cholesterol; LDL-C, low-density lipo-
Table 5 Patient 4: lomitapide treatment details and key lipid parameters
Week
TC, mmol/L
(mg/dL)
TG, mmol/L
(mg/dL)
HDL, mmol/L
(mg/dL)
LDL, mmol/L
(mg/dL)
ALT,
U/L
Lomitapide,
mg Other LLTs Intervention
0 9.0 (348) 0.7 (62) 1.3 (50) 7.3 (282) 42 5 Simva60/Eze10 Start lomitapide
2 9.0 (348) 1.3 (115) 1.5 (58) 6.9 (267) 19 10 Simva60/Eze10/LA Escalate lomitapide
3 9.4 (363) 1.0 (89) 1.4 (54) 7.6 (294) 44 10 Simva60/Eze10/LA
5 6.1 (236) 0.7 (62) 1.2 (46) 4.6 (178) — 10 Simva60/Eze10/LA
6 5.7 (220) 0.8 (71) 1.2 (46) 4.1 (159) — 20 Simva60/Eze10 Escalate lomitapide
8 4.6 (178) 0.4 (35) 1.0 (39) 3.3 (128) — 20 Simva40/Eze10/LA Reduce Simva dose
9 3.4 (131) 0.6 (53) 1.1 (43) 2.0 (77) 31 20 Simva40/Eze10
10 3.6 (139) 0.5 (44) 1.2 (46) 2.2 (85) — 20 Simva40/Eze10
14 4.9 (189) 0.6 (53) 1.3 (50) 3.4 (131) 61 20 Simva40/Eze10
16 4.3 (166) 0.6 (53) 0.9 (35) 3.2 (124) — 20 Simva40/Eze10/LA
19 4.3 (166) 0.5 (44) 1.3 (50) 2.8 (108) — 20 Simva40/Eze10/LA
22 5.6 (217) 0.5 (44) 1.5 (58) 3.9 (151) 33 20 Simva40/Eze10
24 4.7 (182) 0.5 (44) 1.1 (43) 3.4 (131) — 20 Simva40/Eze10/LA
ALT, alanine aminotransferase; Eze, ezetimibe (number denotes dose in mg); HDL, high-density lipoprotein; LA, lipoprotein apheresis; LDL, low-
density lipoprotein; LLT, lipid-lowering therapy; Simva, simvastatin (number denotes dose in mg); TC, total cholesterol; TG, triglycerides.
614 Journal of Clinical Lipidology, Vol 9, No 4, August 2015observed with conventional lipid-lowering medications,
when used alone. Use of lomitapide in these 4 patients
resulted in significant and clinically meaningful decreases
in LDL-C for each patient, between 35% and 83% from
baseline levels. The addition of lomitapide does require
careful monitoring of transaminases for hepatic impairment.
Adherence to a low-fat eating plan (,20% calories from
fat) is also important to minimize GI AEs, which were the
most common AEs observed in the clinical trial. Of the 4
patients, 3 remain on lomitapide treatment and 1 discon-
tinued lomitapide treatment because of the level of ALT
elevations, which resolved to normal after discontinuation.
Patient 1 exemplifies how GI side effects can be suc-
cessfully managed by close adherence to a low-fat diet. This
patient experienced GI side effects with the lowest dose of
lomitapide (5 mg), but required dose escalation in the
interests of efficacy. The dose was increased to 10 mg,
which resulted in an apparent spontaneous resolution of
symptoms provided the diet was followed. Further escala-
tion to 20 mg saw the return of some GI symptoms, but with
experience, the patient learned to manage GI events by
ensuring that she ate every w2 h. This case demonstrates
how adaptations to the required low-fat diet can assist in the
management of the GI side effects of lomitapide.
The prescribing information for lomitapide is some
important dietary modifications that must be followed for
patients receiving lomitapide to lessen the impact of AEs.
Clinical experience (such as in patient 1) has demonstrated
that adhering to these dietary modifications can have a
positive impact on the tolerability, compliance, and success
of lomitapide therapy. The occurrence and severity of GI
AEs associated with the use of lomitapide decreases if a
low-fat diet is consumed; therefore, patients should follow
a diet supplying ,20% of energy from fat before initiating
lomitapide treatment and should continue this diet during
treatment. Dietary counseling should be provided.17 In clin-
ical studies, lomitapide treatment was associated withdecreased levels of essential fatty acids and vitamin E.
Therefore, to maintain essential fatty acids and vitamin E
within normal limits, patients should be advised to take
daily dietary supplements that provide 400 IU of vitamin
E, as well as at least 200 mg linoleic acid, 110 mg eicosa-
pentaenoic acid, 210 mg alpha lipoic acid, and 80 mg
docosahexaenoic acid per day, throughout lomitapide
treatment.17
Patient 4 highlights how lomitapide may provide benefit
beyond pre-existing treatment. This patient was diagnosed
with HoFH at an early age and had become accustomed to
LA from the age of 9 years. The patient was, in general,
tolerant to this treatment, but the ‘‘see–saw’’ kinetics
of LDL-C for LA meant that time-averaged exposure
to elevated LDL-C levels remained higher than European
Atherosclerosis Society-recommended treatment targets.6
In the case of patient 4, despite the fact that he was
accustomed and satisfied with LA therapy, an underlying
long-term risk remained. When lomitapide was added to his
pre-existing therapeutic regimen of LA, the patient’s
LDL-C levels dropped 73% from baseline. Although the
patient did not stop LA, the treatment interval was
extended.
Because of the mechanism of action of lomitapide,
accumulation of liver fat while on therapy is not unex-
pected.20 Therefore, there is concern if a patient presents
with pre-existing hepatic steatosis, which is not uncommon
in patients with obesity or type II diabetes.21,22 Both
patients 2 and 3 presented with moderate hepatic steatosis
(as evidenced from ultrasound and FibroScan), before treat-
ment with lomitapide although other hepatic parameters
were normal at baseline. In patient 3, additional hepatic
complications did not arise while on therapy, and this
patient continues with the treatment. This case illustrates
that, although MTP inhibition causes accumulation of
hepatic fat,20 close monitoring of steatosis and LFTs have
the potential to enable successful and well-tolerated
Figure 7 Algorithm for managing hepatic parameters in patients receiving lomitapide. Contraindications: hypersensitivity to the active
substance or to any of the excipients listed in section 6.1 of the product information,17 pregnancy, moderate or severe hepatic impairment,
unexplained persistent abnormal LFTs, known significant or chronic bowel disease, concomitant administration of .40 mg simvastatin,
strong or moderate cytochrome P450 (CYP) 3A4 inhibitors human immunodeficiency virus protease inhibitors, diltiazem, verapamil, or
dronedarone. ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international normalized ratio; LFT, liver function
test; ULN, upper limit of normal.
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individual basis in our patients.
The European Summary of Product Characteristics for
lomitapide suggests regular hepatic screening, including the
use of imaging17; however, imaging is not specifically sug-
gested in the US Product Information.16 In our patients,
FibroScan was used, which uses a transient elastography
method to measure liver stiffness on the basis of transmis-
sibility of vibrations through the liver tissue.23 FibroScan is
considered to be accurate, apart from in obese patients, in
whom there is absorption of ultrasound by subcutaneous
fat.23Lomitapide treatment can cause elevations in ALT and
AST levels; however, the extent to which lomitapide-
associated hepatic steatosis promotes the elevations in
aminotransferase is unknown. As directed by the lomita-
pide summary of product characteristics, LFTs were
monitored closely throughout treatment for all patients.
There were no elevations of concern in ALT/AST levels in
patients 1, 3, and 4, despite moderate baseline hepatic
steatosis in patient 3 and some signs of loss of hepatic
elasticity in patient 4. The lomitapide summary of product
characteristics recommends assessment for hepatic steato-
sis through evaluation of biomarkers plus imaging before
616 Journal of Clinical Lipidology, Vol 9, No 4, August 2015treatment with lomitapide and annually thereafter.17 It also
recommends this is done in consultation with a hepatolo-
gist.17 In patient 2, after consultation with a hepatologist,
the risk of CVD was considered to be more threatening
than progression of liver steatosis. Lomitapide therapy
was commenced at 5 mg, resulting in a 46% decrease in
LDL-C levels. At 10-mg lomitapide, LFTs increased to
.5! ULN. Per the summary of product characteristics,
lomitapide was temporarily withheld. After discontinua-
tion, LFTs decreased rapidly, and the patient was able to
start lomitapide again at 5 mg daily, which she tolerated
well for an additional 14 weeks. At that time, her ALT
levels again increased to .3! ULN, and treatment with
lomitapide was permanently stopped. Within 12 weeks of
discontinuation, the patient’s LFT values had decreased to
normal levels. This patient illustrates that regular moni-
toring of LFTs and adherence to the suggested dose adjust-
ment protocol enables successful use of the drug, but
persistent ALT/AST elevations can resolve to normal after
discontinuation of the drug. In a 2014 review, deGoma pro-
vides an overview of the management of HoFH, including a
checklist for initiation of the drug and an algorithm for the
management of AST/ALT elevations, similar to that shown
in Figure 7.24
Given the rarity of HoFH, classic, long-term clinical
study programmes will not provide meaningful population-
level data on the risk–benefit profile of lomitapide, and
effects on cardiovascular mortality and morbidity have not
been determined. Therefore, it is important to observe the
real-world use of drugs for rare diseases in individual
patient cases to understand how to adapt treatment in the
day-to-day clinical setting.
HoFH is not only rare but also historically difficult to
treat. For 3 of the 4 HoFH cases presented here, the efficacy
of lomitapide has been such that LDL-C levels have been
brought under control with AEs that were either mild or
manageable with adherence to dietary recommendations and
protocols for monitoring and adapting to changes in hepatic
parameters. The lomitapide summary of product character-
istics provides an algorithm for management of LFTs,
which is summarized in Figure 7, and which highlights the
need to consider pre-existing hepatotoxicity and to make
individualized and proportional responses to elevated LFTs.
Notably, all 4 of the patients described here had genetic
confirmation of HoFH. In practice, this is not always
possible, for example, because of limited access to testing.
A positive genetic test for HoFH is not mandatory for the
use of lomitapide.17 In cases where a genetic test is either
not available or reliable, diagnosis is based on clinical find-
ings and family history.6 It is noteworthy that wide vari-
ability in LDL-C levels for both treated and untreated
HoFH has been described.25
In general, the clinical trial programme and the clinical
experience in cases such as those described here, have
shown that lomitapide is an effective LLT with and without
LA when treatment is individualized to the patient’s needs;
however, because of the rarity of HoFH, CVoutcomes havenot been assessed. Lomitapide can cause serious AEs. In
accordance with the Summary of Product Characteristics,
dose titration/stoppage, dietary modification, dietary sup-
plements, and monitoring of LFTs and hepatic steatosis are
required to manage potential AEs.
These real-world case studies highlight that lomitapide
is an option for patients with homozygous FH who are
motivated to adhere to diets and monitoring and for those
treating physicians who are inspired to treat these patients
for whom lipid levels are notoriously difficult to manage.
Lomitapide continues to be examined as part of its
pharmacovigilance programme.Acknowledgment
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